Antabio
PrivateLast Round
Series B
Dec 12, 2023
Total Funding Raised
$83.91M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Antabio is a clinical-stage biopharmaceutical company developing novel antibacterial treatments targeting drug-resistant infections caused by critical priority pathogens.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Antabio Comparables
Compare Antabio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| VenatoRx Pharmaceuticals | 90% | |
| Allecra Therapeutics | 86% | |
| Omnix Medical Ltd. | 84% |
Antabio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Dec 12, 2023 | ||||
| Grant | Jan 6, 2022 | ||||
| Grant | Mar 16, 2021 | ||||
| Grant | Jan 2, 2020 | ||||
| Grant | Nov 13, 2019 | ||||
Series A | Jul 12, 2018 |
Antabio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| AMR Action Fund | Series B |
| CARB-X | Grant |
| BNP Paribas Développement | Series B, Series A |
| iXO Private Equity | Series A |
| Turenne Groupe | Series B |
| Région Occitanie | Grant |
| Galia Gestion | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 1559% MoM.
- May 16, 2026
Monthly visitors grew 2413% MoM, from 46 to 1.2K.
Antabio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Antabio's valuation, stock price, and market status.
Is Antabio a public or private company?
Antabio is a private company.
What is the current stock price of Antabio?
Antabio is a private company, so its shares have no public market price. Caplight tracks Antabio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Antabio worth (valuation)?
Valuation information for Antabio is not publicly available.
Can I buy Antabio stock?
Antabio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Antabio's last funding round?
Antabio's most recent funding round was Series B on December 12, 2023.
Who are the main investors in Antabio?
Key investors in Antabio include CARB-X, Bpifrance, Wellcome Trust, EIC Fund.
Will Antabio IPO soon?
No public IPO plans have been announced for Antabio.
How can I track Antabio secondary market activity?
Caplight tracks bids, offers, and trades in Antabio's shares on secondary markets.